Ironwood Pharmaceuticals, Inc
$2.4M 18,075 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Recordati_rare_diseases_inc.
Recordati_rare_diseases_inc. reported $2,344,877.69 across General Payments, Research, and Ownership to 5,392 physicians and teaching hospitals across 5,992 transactions.
- $2.3M Top quartile payer
- All-tracks total
- 5,992 Top quartile volume
- Transactions
- 5,392 Top quartile reach
- Recipients
- +$581.5K
- General Payments vs PY2023
Recordati_rare_diseases_inc. reported $2,344,877.69 across all CMS Open Payments tracks (General + Research + Ownership) to 5,392 physicians and teaching hospitals in Program Year 2024 - ranking #417 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $714,168.60, averaging $434.88 per recipient.
How Recordati_rare_diseases_inc.'s $2.3M all-tracks total breaks down
Recordati_rare_diseases_inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
57/100
Total payments
F
32/100
Transaction volume
D
54/100
Physician reach
D
51/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer recordati-rare-diseases-inc Recordati_rare_diseases_inc.
$2.3M · #417/1,925 · 0.0% industry · PY2024
- TOT $2.3M
- RANK #417
- SHARE 0.0%
- TXN 5,992
- RCP 5,392
- CAT 7
- GEN $714.2K
- ΔGEN +$581.5K
- TOP1 7.9%
- PY 2024
Volume peers
Nearest volume peer: Ironwood Pharmaceuticals, Inc ($2.4M)
Recordati_rare_diseases_inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Recordati_rare_diseases_inc.'s CMS-reported General Payments increased by $581.5K (+438.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: RECORDATI_RARE_DISEASES_INC.PY2023: RECORDATI_RARE_DISEASES_INC.PY2024: RECORDATI_RARE_DISEASES_INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $132,628.81
- PY2024
- $714,168.60
What the Data Shows for Recordati_rare_diseases_inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Recordati_rare_diseases_inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 7-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $355.0K, accounting for 49.7% of this company's General Payments and 119 transactions.
General Payment Breakdown by Type
"Honoraria" leads Recordati_rare_diseases_inc.'s 7-category general-payment breakdown at $355.0K, 49.7% of the reported total.
Recordati_rare_diseases_inc. reports 7 general-payment categories - the top three are Honoraria (49.7%), Consulting Fee (24.1%), and Food and Beverage (16.7%). The remaining 4 categories make up 9.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Recordati_rare_diseases_inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $355.0K | 119 | 49.7% |
| Consulting Fee | $171.8K | 69 | 24.1% |
| Food and Beverage | $118.9K | 5,092 | 16.7% |
| Travel and Lodging | $46.0K | 73 | 6.4% |
| Compensation for Services Other Than Consulting | $20.3K | 36 | 2.8% |
| Education | $1.1K | 1 | 0.2% |
| Charitable Contribution | $1.0K | 2 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $190,898.50 (26.7%) of $714,168.60 in this company's General Payments records across 2,758 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Recordati_rare_diseases_inc.
The five named recipients with the highest reported General Payments from this company
- 1
Elena Christofides
$56,440.04 across 38 reported transactions
- 2
Corey Casper
$35,754.80 across 20 reported transactions
- 3
Maria Fleseriu
$34,950.35 across 12 reported transactions
- 4
Wenyu Huang
$32,548.62 across 13 reported transactions
- 5
Gordan Srkalovic
$31,204.69 across 20 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Recordati_rare_diseases_inc. ranks #417 of 1,925 by total payments (top 22% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,511 of 1,838 by HHI (bottom 18% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Averitas Pharma Inc. : $1.5M total payments, HHI 253
- Ambu A/S : $181.1K total payments, HHI 252
- Ivoclar Vivadent, Inc. : $280.4K total payments, HHI 251
- MDD US Operations, LLC : $1.7M total payments, HHI 249
- Olympus Medical Systems Corporation : $242.8K total payments, HHI 248
- Verrica Pharmaceuticals Inc. : $1.1M total payments, HHI 248
- Recordati_rare_diseases_inc. (this company) : $714.2K total payments, HHI 247
- Prism Medical : $34.0K total payments, HHI 247
- Medtronic, Inc. : $117.7M total payments, HHI 247
- Coloplast Corp : $3.4M total payments, HHI 246
- Elevate Surgical CO : $14.4K total payments, HHI 244
- Alcon Vision LLC : $13.4M total payments, HHI 244
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Recordati_rare_diseases_inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Recordati_rare_diseases_inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Recordati_rare_diseases_inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Potrero Medical, Inc.
$2.4M 60 recipients
Compare payment profiles
Axogen
$2.4M 7,770 recipients
Compare payment profiles
Boehringer Ingelheim Pharma GmbH & Co.KG
$2.4M 15 recipients
Compare payment profiles
Checkpoint Surgical, Inc
$2.3M 887 recipients
Compare payment profiles
Urogen Pharma, Inc.
$2.3M 7,857 recipients
Compare payment profiles
Put this to use
Recordati_rare_diseases_inc. ranks #417 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where Recordati_rare_diseases_inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Recordati_rare_diseases_inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.